Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin
- PMID: 9204908
- DOI: 10.1126/science.277.5322.99
Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin
Abstract
The immunosuppressant rapamycin interferes with G1-phase progression in lymphoid and other cell types by inhibiting the function of the mammalian target of rapamycin (mTOR). mTOR was determined to be a terminal kinase in a signaling pathway that couples mitogenic stimulation to the phosphorylation of the eukaryotic initiation factor (eIF)-4E-binding protein, PHAS-I. The rapamycin-sensitive protein kinase activity of mTOR was required for phosphorylation of PHAS-I in insulin-stimulated human embryonic kidney cells. mTOR phosphorylated PHAS-I on serine and threonine residues in vitro, and these modifications inhibited the binding of PHAS-I to eIF-4E. These studies define a role for mTOR in translational control and offer further insights into the mechanism whereby rapamycin inhibits G1-phase progression in mammalian cells.
Similar articles
-
Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.EMBO J. 1996 Oct 1;15(19):5256-67. EMBO J. 1996. PMID: 8895571 Free PMC article.
-
4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway.Genes Dev. 1998 Feb 15;12(4):502-13. doi: 10.1101/gad.12.4.502. Genes Dev. 1998. PMID: 9472019 Free PMC article.
-
Phosphorylation of the eIF4E-binding protein PHAS-I after exposure of PC12 cells to EGF and NGF.FEBS Lett. 1996 Nov 4;396(2-3):165-71. doi: 10.1016/0014-5793(96)01097-6. FEBS Lett. 1996. PMID: 8914981
-
PHAS proteins as mediators of the actions of insulin, growth factors and cAMP on protein synthesis and cell proliferation.Adv Enzyme Regul. 1997;37:239-67. doi: 10.1016/s0065-2571(96)00016-7. Adv Enzyme Regul. 1997. PMID: 9381973 Review.
-
Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling.Curr Opin Immunol. 1998 Jun;10(3):330-6. doi: 10.1016/s0952-7915(98)80172-6. Curr Opin Immunol. 1998. PMID: 9638370 Review.
Cited by
-
Inhibition of PI3K/Akt pathway impairs G2/M transition of cell cycle in late developing progenitors of the avian embryo retina.PLoS One. 2013;8(1):e53517. doi: 10.1371/journal.pone.0053517. Epub 2013 Jan 2. PLoS One. 2013. PMID: 23301080 Free PMC article.
-
Chronic rapamycin treatment or lack of S6K1 does not reduce ribosome activity in vivo.Cell Cycle. 2013 Aug 1;12(15):2493-504. doi: 10.4161/cc.25512. Epub 2013 Jul 1. Cell Cycle. 2013. PMID: 23839034 Free PMC article.
-
Lomitapide repurposing for treatment of malignancies: A promising direction.Heliyon. 2024 Jun 13;10(12):e32998. doi: 10.1016/j.heliyon.2024.e32998. eCollection 2024 Jun 30. Heliyon. 2024. PMID: 38988566 Free PMC article. Review.
-
UV damage induces G3BP1-dependent stress granule formation that is not driven by mTOR inhibition-mediated translation arrest.J Cell Sci. 2020 Oct 28;133(20):jcs248310. doi: 10.1242/jcs.248310. J Cell Sci. 2020. PMID: 32989041 Free PMC article.
-
Targeting tumor-initiating cells: eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction.Oncotarget. 2015 Mar 10;6(7):4585-601. doi: 10.18632/oncotarget.3278. Oncotarget. 2015. PMID: 25671304 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous